In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections
- 1 April 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (4), 479-483
- https://doi.org/10.1128/aac.33.4.479
Abstract
The therapeutic efficacy of orally administered zidovuldine (3'-azido-3'-deoxythymidine) was determined in animals infected with Escherichia coli and Salmonella dublin. The 50% effective dose (ED50) of zidovudine (9.6 to 11.8 mg/kg of body weight) compared favorably with that of trimethoprim (19.4 to 22.2 mg/kg) in mice with systemic E. coli infection. At 50 mg/kg, both zidovudine and ampicillin reduced the number of bacteria in the kidneys of mice and prevented lethal infection in mice with ascending pyelonephritis caused by E. coli. Zidovudine prevented a lethal S. dublin infection in calves over a wide dose range (8.0 to 31.0 mg/kg per day). Zidovudine levels in plasma of uninfected mice were 28.2 +/- 4.5 and 7.9 +/- 2.2 micrograms/ml at 30 and 60 min, respectively, exceeding the MICs for the bacteria used in the infections. Few zidovudine-resistant strains were observed. The in vivo data raise the possibility that zidovudine may have an antibacterial effect in patients receiving this therapy.Keywords
This publication has 12 references indexed in Scilit:
- Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complexAmerican Journal Of Medicine, 1987
- Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseasesCancer Cell, 1987
- Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U)Antimicrobial Agents and Chemotherapy, 1987
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.JCI Insight, 1985
- Mannose-sensitive and Gal-Gal binding Escherichia coli pili from recombinant strains. Chemical, functional, and serological properties.The Journal of Experimental Medicine, 1983
- Appraisal of the suitability of a disease model of acute salmonellosis in calves for chemotherapeutic studiesResearch in Veterinary Science, 1981
- Chemotherapeutic Evaluation of Trimethoprim and Sulphonamides in Experimental Salmonellosis of SheepResearch in Veterinary Science, 1973
- The growth of micro-organismsin vivowith particular reference to the relation between dose and latent periodEpidemiology and Infection, 1958